#Aptamers Market size

[neha24blog]

Aptamers Market Segmented On The Basis Of Type, Application, Technology, End-User, Region And Forecast To 2030: Grand View Research Inc.

Aptamers Market Segmented On The Basis Of Type, Application, Technology, End-User, Region And Forecast To 2030: Grand View Research Inc.

San Francisco, 8 Dec 2022: The Report Aptamers Market Size, Share & Trends Analysis Report By Type (Nucleic Acid (DNA, RNA, XNA), Peptide), By Application (Diagnostics, Therapeutics, Research & Developments, Others), By Technology, by End-user, By Region, And Segment Forecasts, 2022 – 2030 The global aptamers market size is expected to reach USD 10.9 billion by 2030, according to a new report by…

[latestmarketresearchnews]

Aptamers Market - Structure, Size, Trends, Analysis and Outlook 2030

The global aptamers market was valued at USD 1.94 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 24.54% from 2023 to 2030. This rapid growth is being driven by significant advancements in the development, purification, and drug delivery systems for targeting and eliminating harmful cells, which have garnered the attention of researchers. Aptamers possess several competitive advantages over traditional antibodies, including smaller molecular size, lower immunogenicity (reduced immune response), reduced manufacturing costs, and fewer side effects. These benefits are encouraging research and development (R&D) efforts in the creation of new aptamers, fueling market expansion.

Despite considerable research, no highly effective treatments for COVID-19 have been identified, partly due to the virus's extensive genetic mutations. However, biotechnological approaches, including the use of aptamers, hold promise in combating COVID-19 infections. Nucleic acid-based aptamers and peptide aptamers are believed to offer potential therapeutic solutions for the virus, and various government initiatives are supporting the development of novel treatments for COVID-19. For example, in September 2020, the Department of Community & Economic Development awarded USD 320,000 to Aptagen LLC to fund research and development of a novel COVID-19 treatment. This investment reflects the growing recognition of aptamers' potential in addressing unmet medical needs.

Gather more insights about the market drivers, restrains and growth of the Aptamers Market

Aptamers are also proving valuable in diagnostics. Using SELEX (Systematic Evolution of Ligands by Exponential Enrichment) technology, aptamer-based diagnostic kits and assays can develop high-affinity neutralizers and bioprobes for detecting SARS-CoV-2 and other COVID-19 biomarkers. These innovations are expected to further drive market growth. For example, in December 2021, Achiko AG received approval from the Indonesian Ministry of Health for its COVID-19 diagnostic kit, Aptamex. Aptamex is a second-generation, cost-effective diagnostic tool based on DNA aptamer technology, representing an emerging solution in healthcare diagnostics.

Type Segmentation Insights:

The aptamers market is segmented into nucleic acid aptamers and peptide aptamers. In 2022, the nucleic acid aptamers segment dominated the market, holding a 78.19% share, and is expected to exhibit the highest growth during the forecast period. Many companies are actively exploring the therapeutic mechanisms of nucleic acid aptamers for treating various disorders, such as age-related macular degeneration (AMD). For instance, in June 2021, the U.S. Food and Drug Administration (FDA) granted IVERIC BIO (formerly Ophthotech Corporation) a written agreement under the Special Protocol Assessment (SPA) for the design of its phase 3 clinical trial, GATHER2. The trial aims to assess the efficacy of Zimura, a nucleic acid aptamer-based drug, for patients with geographic atrophy (GA) secondary to AMD. This FDA approval is expected to significantly bolster the growth of the nucleic acid aptamer segment.

The peptide aptamer segment is anticipated to experience substantial growth, with a projected CAGR of 22.77% from 2023 to 2030, driven by its broad applications in diagnostics and therapeutics. For instance, in August 2021, scientists from the Engineering Center for Microtechnology and Diagnostics developed an innovative biosensor for multiparametric express testing in the preclinical diagnostics of cardiovascular diseases. This testing uses next-generation biochips, which are based on a peptide aptamer marker system and molecular recognition technology. The researchers designed peptide aptamers using data from the Data Bank and Protein 3D software. The introduction of such advanced products in the market is likely to increase the utilization of peptide aptamers, contributing to the segment's growth.

In summary, the aptamers market is poised for rapid expansion due to the advantages of aptamers in therapeutic and diagnostic applications, advancements in technology, and ongoing R&D efforts. The market's growth is further supported by government initiatives, regulatory approvals, and the increasing use of aptamer-based solutions in areas such as COVID-19 treatment, diagnostics, and the management of other medical conditions.

Order a free sample PDF of the Aptamers Market Intelligence Study, published by Grand View Research.

[marketresearchreportinsight]

Aptamers Market by Revenue, Growth Rate and Forecast to 2030

The global aptamers market was valued at USD 1.94 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 24.54% from 2023 to 2030. This rapid growth is being driven by significant advancements in the development, purification, and drug delivery systems for targeting and eliminating harmful cells, which have garnered the attention of researchers. Aptamers possess…

[industrynewsupdates]

Aptamers Market Size, Key Companies, Trends, Growth and Forecast Report, 2030

The global aptamers market size is expected to reach USD 10.88 billion by 2030, according to a new report by Grand View Research Inc. The market is expected to expand at a CAGR of 24.54% from 2023 to 2030.  The growth of the market is attributed to the strong presence of product pipelines and their expected launch during the forecast period. Some of the products in the pipeline are E10030 (Fovista), ARC1905 (Zimura) by IVERIC Bio, Inc., AGRO100 by Antisoma Research Ltd, NOX-A12 (olaptesed pegol) & NOX-E36 (emapticap pegol) by NOXXON Pharma, and NU172 by ARCA Biopharma, Inc. AGRO100 completed the phase 1 clinical trial for multiple oncology indications such as non-small cell lung cancer, solid tumors, and renal cancer.

In addition, initiatives undertaken by regulatory agencies such as the U.S. FDA, Health Canada, EMA, COFEPRIS, MHRA, and CDSCO to support the research and development in the field of aptamers are projected to fuel market growth. For instance, in March 2020, IVERIC Bio, Inc. received Fast Track designation from the U.S. FDA for Zimura for the treatment of patients with GA secondary to age-related macular degeneration (AMD). Zimura is a chemically synthesized pegylated RNA aptamer, administered by intravitreal injection. It acts by inhibiting complement factor C5 which is responsible for the development of AMD.

Companies are studying aptamers for applications such as western blotting, ELISA, therapeutics, and flow cytometry. Custom aptamer selection is considered to be an important service offered by existing aptamer players to life sciences companies. Thrombin aptamers, cocaine aptamers, and theophylline aptamers are some of the most frequently used customized aptamers for research and development activities. Thus, the surge in numbers of biotech and pharma companies working on research related to aptamers and related technologies has opened up new avenues for the growth of this market.

Gather more insights about the market drivers, restrains and growth of the Aptamers Market

Detailed Segmentation:

Type Insights

Based on type, aptamers market is segmented into nucleic acid aptamers and peptide aptamers. Nucleic acid segment held the highest market share of 78.19% in 2022 and is expected to witness the highest growth during the forecast period. At present, many companies are investigating the mechanism of action of nucleic acid aptamers for the treatment of various disorders including age related muscular degeneration (AMD). For instance, in June 2021, the U.S. Food and Drug Administration (FDA) granted written agreement under Special Protocol Assessment (SPA) to IVERIC BIO (formerly known as Ophthotech Corporation) for the design of GATHER2 phase 3 clinical trial of Zimura for treatment of patients with GA secondary to AMD. This approval is expected to boost the segment growth.

Application Insights

Based on application, the aptamers market is segmented into diagnostics, therapeutics development, research and development, and others. The research & development segment held the highest market share of 31.38% in 2022. The growth of segment is attributed to rising demand for aptamers coupled with increasing research activities in this field have paved the way for aptamers demand in research and development field. There are various strategic initiatives undertaken by key players like collaborations, partnerships, & agreements for R&D of novel aptamers based diagnostic and therapeutic products. For instance, in June 2021, SomaLogic and Ixaka Ltd entered into a research collaboration with an aim to support the discovery and development of aptamers based bispecific therapeutics. This collaboration evaluates the safety and efficacy of antigen specific SOMAmer reagents. Such an initiative is expected to boost the segment growth.

Regional Insights

North America region dominated the aptamers market with a share of 44.48% in 2022. The rising prevalence of chronic diseases, strong healthcare infrastructure, and growing interest of research laboratories in aptamer field are some of the major factors for the dominance of the region. Furthermore, in April 2022, Noxxon Pharma announced that it will present top line result data for its NOX-A12 GLORIA trial in brain cancer at the 2022 American Society of Clinical Oncology annual meeting.

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global live cell imaging market size was valued at USD 2.48 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 9.0% from 2024 to 2030.

• The global market for cell-free protein expression reached a value of USD 267.4 million in 2023 and is projected to grow at a CAGR of 8.6% from 2024 to 2030.

Key Companies & Market Share Insights

Major players are adopting strategies such as modification in the existing product, approval of new products, and mergers & acquisitions for product enhancements and regional expansion to attain a greater market share. For instance, in January 2023, Aptamer Group collaborated with BaseCure Therapeutics for the development of Optimer-targeted therapies. Such initiatives can open new avenues of growth for applications of aptamers in therapeutics. 

Some of the prominent players in the global aptamers market include:

• SomaLogic

• Aptamer Group

• Aptadel Therapeutics

• Base Pair Biotechnologies

• Noxxon Pharma

• Vivonics Inc.

• Aptagen, LLC

• TriLink Biotechnologies

• Altermune LLC

• AM Biotechnologies

Aptamers Market Segmentation

Grand View Research has segmented the global aptamers market on the basis of type, application, and region:

Aptamers Type Outlook (Revenue, USD Million; 2018 - 2030)

• Nucleic Acid Aptamer

• Peptide Aptamer

Aptamers Application Outlook (Revenue, USD Million; 2018 - 2030)

• Diagnostics

• Therapeutics

• Research & Development

• Others

Aptamers Regional Outlook (Revenue, USD Million; 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o Germany

o UK

o France

o Italy

o Spain

o Denmark

o Sweden

o Norway

• Asia Pacific

o Japan

o China

o India

o Australia

o Thailand

o South Korea

• Latin America

o Brazil

o Mexico

o Argentina

• MEA

o South Africa

o Saudi Arabia

o UAE

o Kuwait

Order a free sample PDF of the Aptamers Market Intelligence Study, published by Grand View Research.

[mrfr-blogs]

Trends Influencing the Future of Aptamers Market

Market Overview –

Aptamers market size is expected to reach USD 2.3 billion by 2022. The Aptamers market industry is expected to increase from USD 2.74 billion in 2023 to USD 11.42 billion in 2032, with a compound annual growth rate (CAGR) of 19.50% during the forecast period (2023-2032).

The Aptamers Market is expanding rapidly, driven by the increasing interest in aptamer therapeutics for various medical applications. Aptamers are single-stranded DNA or RNA molecules that bind to specific targets, offering potential advantages over traditional therapeutics. The market offers a range of aptamer-based drugs and diagnostics, promising innovative solutions for treating diseases and improving patient outcomes.

The aptamers market focuses on a class of molecules known as aptamers, which are short, single-stranded DNA or RNA sequences that bind to specific target molecules with high affinity and specificity. Aptamers are used in various applications, including diagnostics, therapeutics, drug delivery, and research tools.

Market growth is driven by several factors, including the increasing demand for personalized medicine, growing investments in pharmaceutical research and development, and advancements in aptamer technology. As researchers and healthcare providers seek innovative solutions for disease diagnosis and treatment, there is a growing interest in aptamers due to their unique properties, such as high specificity, low immunogenicity, and ease of synthesis.

Technological advancements and innovations in aptamer selection, optimization, and conjugation techniques are shaping the market, offering new opportunities for aptamer-based diagnostics and therapeutics. From cell-SELEX and high-throughput screening methods to aptamer-drug conjugates and targeted delivery systems, these advancements expand the scope of aptamer applications across various biomedical fields.

Moreover, the COVID-19 pandemic has highlighted the potential of aptamers in diagnostics and therapeutics, as researchers rapidly develop aptamer-based assays for virus detection and aptamer-based therapies for COVID-19 treatment. Aptamers offer several advantages over traditional antibodies, including faster development timelines, lower production costs, and greater stability, making them valuable tools in combating emerging infectious diseases.

However, challenges such as limited commercialization of aptamer-based products, regulatory hurdles, and competition from alternative technologies pose obstacles to market growth. Addressing these challenges requires collaboration between aptamer developers, pharmaceutical companies, regulatory agencies, and healthcare providers to validate aptamer-based products, establish standardized protocols, and overcome market barriers.

Segmentation –

The Global Aptamers Market has been segmented based on Type, Application, And End-User.

Based on Type, the market is segmented into Nucleic Acid and Peptide Aptamers. The dominance of the Nucleic Acid category in the Aptamers market can be attributed to the widespread use of nucleic acid-based aptamers, such as DNA and RNA aptamers, due to their high affinity, specificity, and versatility for targeting diverse biomolecules in various applications.

Based on the Application, the market is segmented into Diagnostics and Therapeutics Development. The Diagnostics category primarily focuses on the accurate and timely detection, identification, and monitoring of diseases, conditions, or health parameters through various tests, techniques, and tools.

Based on the Technology, the market is segmented into Selex, X-aptamer, and MARAS techniques. The SELEX category primarily focuses on the systematic evolution of ligands by the exponential enrichment (SELEX) process, which is used to select aptamers with high affinity and specificity for specific target molecules.

Based on the End-User, the market is segmented into Biotechnology and Pharmaceutical Companies. The Biotechnology sector that dominates Aptamers primarily focuses on harnessing the unique properties of aptamers for various applications, including targeted drug delivery, diagnostics, biomarker discovery, and therapeutics development.

Regional Analysis –

The Aptamers Market showcases distinct regional trends influenced by factors such as research funding, technological advancements, and regulatory frameworks. North America leads the market, with the United States at the forefront of aptamer research and development. Advanced biotechnology infrastructure, coupled with substantial investments in R&D, contribute to market dominance in this region.

Europe follows suit, with countries like the UK, Germany, and Switzerland making significant strides in aptamer-based therapeutics and diagnostics. In the Asia Pacific region, increasing focus on precision medicine and growing investments in healthcare innovation propel market growth, particularly in countries like China, Japan, and South Korea. Latin America and the Middle East & Africa regions also show potential for market expansion, albeit with challenges related to infrastructure and regulatory hurdles. Overall, the regional analysis underscores the importance of collaborative efforts between industry stakeholders and policymakers to realize the full potential of aptamer technologies in diverse healthcare settings.

Key Players –

Aptamers companies include SomaLogic Operating Co., Inc., Aptamer Group Inc, Aptagen LLC, Aptamer Sciences Inc., Base Pair Biotechnologies Inc., Aptus Biotech SL, TriLink Biotechnologies, AstraZeneca, AM Biotechnologies, Aptadel Therapeutics, and Ophthotech Corporation.

Related Reports –

Diabetic Ulcer Treatment

Medical Tourniquets

Forensic Swab

Ascites

For more information visit at MarketResearchFuture

[businesspointnews]

Aptamers Market Growth, Trends, Share, Industry Analysis by 2028

IMARC Group, a leading market research company, has recently releases report titled “Aptamers Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028.” The study provides a detailed analysis of the industry, including the global aptamers market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the…

[researchreportinsight]

Aptamers Market Analysis by Application 2030

The global aptamers market was valued at USD 1.94 billion in 2022 and is projected to grow at a significant compound annual growth rate (CAGR) of 24.54% from 2023 to 2030. Aptamers have garnered attention due to recent advancements in their generation, purification, and ability to effectively target and kill specific cells, which make them a powerful tool in therapeutic development.

The COVID-19 pandemic has presented unique challenges in the field of treatment due to the virus's high mutation rate. Currently, there are no fully effective treatments specifically targeting COVID-19 across all its variants. However, aptamers, particularly nucleic acid-based and peptide aptamers, have shown promise as a potential approach to combat COVID-19. The heightened focus on biotechnological solutions for COVID-19 treatment has spurred government and private sector initiatives to accelerate R&D in this area.

One example of government support is a contract awarded in September 2020 by the Department of Community & Economic Development, which allocated USD 320,000 to Aptagen LLC to support the research and development of a novel COVID-19 treatment using aptamers. This financial support aims to foster innovation in developing therapeutic solutions using aptamer technology.

Gather more insights about the market drivers, restrains and growth of the Aptamers Market

Regional Insights:

North America Aptamers Market Trends

North America led the global aptamers market with a 44.48% share in 2022. This dominance can be attributed to several factors:

High Prevalence of Chronic Diseases: Rising rates of chronic illnesses such as cancer, cardiovascular diseases, and neurological disorders have fueled the demand for targeted therapies, boosting interest in aptamer-based treatments.

Robust Healthcare Infrastructure: North America's well-developed healthcare system supports advanced research in biotechnology and pharmaceuticals, facilitating the growth of the aptamers market.

Increased Interest in Aptamer R&D: Research laboratories and institutions in the U.S. and Canada are increasingly focusing on aptamer research to explore novel treatments and diagnostic tools.

An example of North America’s commitment to aptamer R&D is seen in Noxxon Pharma's announcement in April 2022. The company presented the results of its NOX-A12 GLORIA trial for treating brain cancer at the American Society of Clinical Oncology annual meeting, underscoring the region's significant advancements in aptamer-based therapies.

Asia Pacific Aptamers Market Trends

The Asia Pacific region is expected to witness the fastest growth in the aptamers market, with a CAGR of 26.18% during the forecast period. This rapid growth is driven by factors such as:

Approval of New Aptamer-Based Products: Regulatory approvals of aptamer-based products are accelerating market expansion. For instance, Achiko AG entered an agreement in April 2020 with the Pengurus Wilayah Nahdlatul Ulama DKI, a prominent Islamic association in Indonesia, to promote its COVID-19 diagnostic kit AptameX.

Increased Healthcare Demand: As healthcare needs grow, Asia Pacific countries, particularly China, Japan, and India, are adopting advanced technologies and investing in biotechnology.

The collaboration between Achiko AG and Pengurus Wilayah Nahdlatul Ulama DKI in Indonesia highlights the potential for aptamer-based products in diagnostic applications. This organization, which has around 90 million members, offers a significant market for innovative diagnostic tools, particularly as they address the ongoing COVID-19 pandemic.

Browse through Grand View Research's Category Biotechnology Industry Research Reports.

The global plasma fractionation market size was estimated at USD 35.8 billion in 2024 and is projected to grow at a CAGR of 8.5% from 2025 to 2030.

The global sickle cell anemia testing and screening market size was estimated at USD 425.7 million in 2024 and is projected to grow at a CAGR of 12.1% from 2025 to 2030.

Key Companies & Market Share Insights:

Leading companies in the aptamers market are actively pursuing strategies to enhance their product offerings and expand their market presence. These strategies include:

Product Modification: Companies are refining their existing aptamer products to improve efficacy and applicability across various therapeutic areas.

New Product Approvals: Firms are seeking regulatory approvals for novel aptamer-based products to strengthen their market share.

Mergers and Acquisitions: Strategic mergers and acquisitions are helping companies expand their product portfolios and enter new regional markets.

For instance, in January 2023, Aptamer Group announced a collaboration with BaseCure Therapeutics to develop Optimer-targeted therapies. Optimer technology is designed to enhance aptamer-targeted therapeutics, allowing for more precise drug delivery to target cells. This collaboration demonstrates the potential for aptamers in therapeutic applications and reflects the ongoing trend of partnerships within the industry aimed at driving innovation and broadening the use of aptamers in medical treatments.

Key Aptamers Companies:

SomaLogic

Aptamer Group

Aptadel Therapeutics

Base Pair Biotechnologies

Noxxon Pharma

Vivonics Inc.

Aptagen, LLC

TriLink Biotechnologies

Altermune LLC

AM Biotechnologies

Order a free sample PDF of the Aptamers Market Intelligence Study, published by Grand View Research.

[surbhijamdade]

Revenue Forecast and Competitive Landscape for the Oligonucleotide Synthesis Market

The Oligonucleotide Synthesis Market Report for 2024 provides a comprehensive overview of the Oligonucleotide Synthesis Market industry, presenting crucial data and insights into market dynamics, including growth drivers, challenges, and future potential. The report evaluates the Oligonucleotide Synthesis Market Components, focusing on significant opportunities and trends that could shape the industry's trajectory.

According to Straits Research, the global Oligonucleotide Synthesis Market market size was valued at USD 7.74 billion in 2023. It is projected to reach from USD 8.84 billion in 2024 to USD 25.57 billion by 2032, growing at a CAGR of 14.2% during the forecast period (2024–2032).

Get a Sample PDF/Excel of report starting from USD 995 :https://straitsresearch.com/report/oligonucleotide-synthesis-market/request-sample

Top Key Players of Oligonucleotide Synthesis Market :

Agilent Technologies, Inc.

ATDBio Ltd.

TriLink BioTechnologies LLC

Thermo Fisher Scientific

Nitto Denko Corporation

Merck KGaA

LGC Biosearch Technologies

Integrated DNA Technologies, Inc.

GenScript

GE Healthcare

Eurogentec

Eurofins

and more....

Key Insights from the Oligonucleotide Synthesis Market Report

Market Size Overview: The report provides comprehensive estimates of the Oligonucleotide Synthesis Marketsize, including value and sales volume, for the period.

Market Trends and Dynamics: An analysis of the key drivers, opportunities, challenges, and risks shaping the Oligonucleotide Synthesis Market.

Global Economic and Regional Impact: Evaluation of the effects of global inflation and the Russia-Ukraine conflict on the Oligonucleotide Synthesis Market.

Trade Flow Analysis: Detailed examination of import and export volumes of Oligonucleotide Synthesis Marketacross major regions.

Industry Value Chain: Insight into the Oligonucleotide Synthesis Marketvalue chain, covering raw materials, suppliers, manufacturing processes, distributors, and downstream customers.

Industry News, Policies, and Regulations: Coverage of the latest developments, policies, and regulations impacting the Oligonucleotide Synthesis Market.

Regional Analysis for Oligonucleotide Synthesis Market:

The regional analysis section of the report offers a thorough examination of the global Oligonucleotide Synthesis Market market, detailing the sales growth of various regional and country-level markets. It includes precise volume analysis by country and market size analysis by region for both past and future periods. The report provides an in-depth evaluation of the growth trends and other factors impacting the Oligonucleotide Synthesis Market market in key countries, such as the United States, Canada, Mexico, Germany, France, the United Kingdom, Russia, Italy, China, Japan, Korea, India, Southeast Asia, Australia, Brazil, and Saudi Arabia. Moreover, it explores the progress of significant regional markets, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

Oligonucleotide Synthesis Market Segmentations:

By Product Type

Synthesized Oligonucleotide Product

Reagents

Equipment

By Applications

Research

PCR

Sequencing

Gene Synthesis

Diagnostics

Therapeutics

RNAi

Nucleic Acid Aptamers

Others

By End-User

Academic Research Institutes

Pharmaceutical and Biotechnology Companies

Diagnostic Laboratories

Others

Get Detail Market Segmentation :https://straitsresearch.com/report/oligonucleotide-synthesis-market/segmentation

Unit Economics must be known by C-suite professionals:

Cost of Goods Sold (COGS): Includes material, labor, and overhead costs in manufacturing.

R&D Costs: Investment in innovation and compliance with regulations.

Engineering and Design Costs: Resources for design, prototyping, and meeting technical standards.

Production Costs: Specialized manufacturing and quality control expenses.

Supply Chain Costs: Managing procurement and logistics for specialized components.

Testing and Quality Assurance: Costs for ensuring product safety and reliability.

SG&A Costs: Marketing, sales, and administrative expenses.

Revenue per Unit: Income from contracts, services, and licensing.

Gross Margin: Revenue minus COGS, showing unit profitability.

Break-even Analysis: Units or contracts needed to cover total costs.

Customer Acquisition Cost (CAC): Costs to secure new contracts.

Lifetime Value (LTV): Total revenue from a customer over time.

Capital Expenditure (CapEx): Investments in facilities and technology.

Economies of Scale: Cost reductions in larger production runs.

Profit Margin: Final profit after all expenses.

Top Reasons to Choose This Report

Access to Comprehensive Insights: Gain access to extensive analysis, research, and data that are often challenging to gather independently. This report provides valuable information, saving you significant time and effort.

Support for Informed Decisions: Enhance your decision-making process with in-depth insights into market trends, consumer behavior, and key industry factors. This report is essential for strategic planning, including investments, product development, and marketing strategies.

Gain a Competitive Edge: Stay competitive by understanding market dynamics and competitor strategies. The report provides detailed insights into competitor performance and market trends, helping you craft effective business strategies.

Cost-Effective Research Solution: Save on research costs by investing in this report, which offers a detailed and comprehensive analysis of the market. This cost-effective option eliminates the need for extensive independent research.

COVID-19 Aftermath and Geopolitical Influences: Russia-Ukraine Conflict and Middle East Crisis

The report explores the multifaceted impact of COVID-19 on the Oligonucleotide Synthesis Market market, covering both direct and indirect effects across global and local levels. It discusses market size, trends, and growth trajectories in the Oligonucleotide Synthesis Market , classified by type, application, and customer sector. Additionally, it provides a detailed evaluation of market development components before and after the pandemic, supported by a PESTEL analysis to assess key influencers and barriers to market entry. We offer the flexibility to customize the report based on specific regions, applications, or any other statistical details. Our goal is to align our analysis with your specific needs, ensuring a more complete market study. The final report will also examine the impact of the Russia-Ukraine War on the Oligonucleotide Synthesis Market market, assessing how these geopolitical events are influencing current market conditions and future opportunities.

This Report is available for purchase on :https://straitsresearch.com/buy-now/oligonucleotide-synthesis-market

About Us:

Straits Research is a leading research and intelligence organization, specializing in research, analytics, and advisory services along with providing business insights & research reports.

Contact Us: email: sales@straitsresearch.com Address: 825 3rd Avenue, New York, NY, USA, 10022 Tel: +1 646 905 0080 (U.S.) +91 8087085354 (India) +44 203 695 0070 (U.K.)

[marketanalysisdata]

Aptamers Market In-Depth Analysis of Industry Share, Growth Outlook 2030

The global aptamers market was valued at USD 1.94 billion in 2022 and is projected to expand with a robust compounded annual growth rate (CAGR) of 24.54% from 2023 to 2030. The rise in interest among researchers in aptamers is driven by advancements in aptamer generation, purification, and targeted drug delivery techniques that kill target cells. Aptamers offer competitive advantages, such as small molecular size, low immunogenicity, cost-effective manufacturing, and fewer side effects compared to antibodies. These advantages are likely to fuel research and development (R&D) in novel aptamer technologies, subsequently propelling the growth of the aptamers market. Despite significant global research efforts, highly effective treatments for COVID-19 remain limited due to extensive genetic mutations of the virus. However, aptamer-based biotechnological approaches present a promising potential in COVID-19 treatment.

Aptamer-based diagnostic products are increasingly preferred by diagnostic and pathology laboratories for disease diagnosis at the cellular level, given their small size, high specificity, selectivity, and efficacy. The prevalence of diseases such as cancer, cardiovascular disease (CVD), and age-related macular degeneration (AMD) is anticipated to lead to a higher patient turnout in laboratories for diagnostic purposes, boosting demand for aptamer-based diagnostic products. Cancer Research UK projects that approximately 27.5 million individuals could be diagnosed with cancer by 2040, underscoring the increasing need for advanced diagnostics.

Gather more insights about the market drivers, restrains and growth of the Aptamers Market

In March 2022, SomaLogic initiated the assay of samples through its SomaScan Assay for the European Prospective Investigation into Cancer and Nutrition (EPIC) study, analyzing 210 million protein measurements from 30,000 samples. This large-scale study aims to support cancer prediction by enhancing the understanding of cancer, potentially addressing the rising demand for cancer diagnostics and contributing to market growth.

Currently, Macugen, developed by Eyetech Pharmaceuticals, Inc. (now commercialized by Bausch Health Companies Inc.), remains the only FDA-approved therapeutic aptamer in the U.S. since its approval in 2004. It is prescribed for treating AMD. Ongoing technological advances in research continue to direct scientific focus toward developing new aptamer-based drugs to treat various conditions. Several products are in clinical trials, including Zimura, developed by IVERIC Bio, Inc., for treating AMD. The anticipated approval of such drugs could further stimulate market growth in the near future.

Application Segmentation Insights:

The aptamers market is segmented based on application into diagnostics, therapeutics development, research and development, and others. The research and development (R&D) segment accounted for the largest market share at 31.38% in 2022, driven by the rising demand for aptamers and increasing R&D activity in the field. Key players have pursued various strategic initiatives, such as collaborations, partnerships, and agreements to support aptamer-based diagnostics and therapeutic development. For instance, in June 2021, SomaLogic and Ixaka Ltd entered into a research partnership to facilitate the discovery and development of bispecific therapeutics using aptamers. This partnership specifically explores the safety and efficacy of antigen-specific SOMAmer reagents, which is expected to further boost growth in the R&D segment.

The therapeutics segment is anticipated to grow rapidly, with a projected CAGR of 26.08% from 2023 to 2030. Aptamers offer several advantages over traditional protein therapeutics, including the ability to design antidotes in a targeted way (a challenge with antibodies), synthetic accessibility, and modifications through medicinal chemistry. These factors collectively enhance the therapeutic segment's market strength. However, therapeutic aptamers face challenges with nuclease resistance, which could potentially hinder growth in this segment.

Order a free sample PDF of the Aptamers Market Intelligence Study, published by Grand View Research.

[marketstudyreport]

Aptamers Market Leading Players, Technological Analysis And Forecast till 2030

The global aptamers market was valued at USD 1.94 billion in 2022 and is projected to expand with a robust compounded annual growth rate (CAGR) of 24.54% from 2023 to 2030. The rise in interest among researchers in aptamers is driven by advancements in aptamer generation, purification, and targeted drug delivery techniques that kill target cells. Aptamers offer competitive advantages, such as small molecular size, low immunogenicity, cost-effective manufacturing, and fewer side effects compared to antibodies. These advantages are likely to fuel research and development (R&D) in novel aptamer technologies, subsequently propelling the growth of the aptamers market. Despite significant global research efforts, highly effective treatments for COVID-19 remain limited due to extensive genetic mutations of the virus. However, aptamer-based biotechnological approaches present a promising potential in COVID-19 treatment.

Aptamer-based diagnostic products are increasingly preferred by diagnostic and pathology laboratories for disease diagnosis at the cellular level, given their small size, high specificity, selectivity, and efficacy. The prevalence of diseases such as cancer, cardiovascular disease (CVD), and age-related macular degeneration (AMD) is anticipated to lead to a higher patient turnout in laboratories for diagnostic purposes, boosting demand for aptamer-based diagnostic products. Cancer Research UK projects that approximately 27.5 million individuals could be diagnosed with cancer by 2040, underscoring the increasing need for advanced diagnostics.

Gather more insights about the market drivers, restrains and growth of the Aptamers Market

In March 2022, SomaLogic initiated the assay of samples through its SomaScan Assay for the European Prospective Investigation into Cancer and Nutrition (EPIC) study, analyzing 210 million protein measurements from 30,000 samples. This large-scale study aims to support cancer prediction by enhancing the understanding of cancer, potentially addressing the rising demand for cancer diagnostics and contributing to market growth.

Currently, Macugen, developed by Eyetech Pharmaceuticals, Inc. (now commercialized by Bausch Health Companies Inc.), remains the only FDA-approved therapeutic aptamer in the U.S. since its approval in 2004. It is prescribed for treating AMD. Ongoing technological advances in research continue to direct scientific focus toward developing new aptamer-based drugs to treat various conditions. Several products are in clinical trials, including Zimura, developed by IVERIC Bio, Inc., for treating AMD. The anticipated approval of such drugs could further stimulate market growth in the near future.

Application Segmentation Insights:

The aptamers market is segmented based on application into diagnostics, therapeutics development, research and development, and others. The research and development (R&D) segment accounted for the largest market share at 31.38% in 2022, driven by the rising demand for aptamers and increasing R&D activity in the field. Key players have pursued various strategic initiatives, such as collaborations, partnerships, and agreements to support aptamer-based diagnostics and therapeutic development. For instance, in June 2021, SomaLogic and Ixaka Ltd entered into a research partnership to facilitate the discovery and development of bispecific therapeutics using aptamers. This partnership specifically explores the safety and efficacy of antigen-specific SOMAmer reagents, which is expected to further boost growth in the R&D segment.

The therapeutics segment is anticipated to grow rapidly, with a projected CAGR of 26.08% from 2023 to 2030. Aptamers offer several advantages over traditional protein therapeutics, including the ability to design antidotes in a targeted way (a challenge with antibodies), synthetic accessibility, and modifications through medicinal chemistry. These factors collectively enhance the therapeutic segment's market strength. However, therapeutic aptamers face challenges with nuclease resistance, which could potentially hinder growth in this segment.

Order a free sample PDF of the Aptamers Market Intelligence Study, published by Grand View Research.

[latestmarketresearchnews]

Aptamers Industry 2030 Size, Share, Business Growth, Demand and Applications

The global aptamers market was valued at USD 1.94 billion in 2022 and is projected to grow at a significant compound annual growth rate (CAGR) of 24.54% from 2023 to 2030. Aptamers have garnered attention due to recent advancements in their generation, purification, and ability to effectively target and kill specific cells, which make them a powerful tool in therapeutic development.

The COVID-19 pandemic has presented unique challenges in the field of treatment due to the virus's high mutation rate. Currently, there are no fully effective treatments specifically targeting COVID-19 across all its variants. However, aptamers, particularly nucleic acid-based and peptide aptamers, have shown promise as a potential approach to combat COVID-19. The heightened focus on biotechnological solutions for COVID-19 treatment has spurred government and private sector initiatives to accelerate R&D in this area.

One example of government support is a contract awarded in September 2020 by the Department of Community & Economic Development, which allocated USD 320,000 to Aptagen LLC to support the research and development of a novel COVID-19 treatment using aptamers. This financial support aims to foster innovation in developing therapeutic solutions using aptamer technology.

Gather more insights about the market drivers, restrains and growth of the Aptamers Market

Regional Insights:

North America Aptamers Market Trends

North America led the global aptamers market with a 44.48% share in 2022. This dominance can be attributed to several factors:

High Prevalence of Chronic Diseases: Rising rates of chronic illnesses such as cancer, cardiovascular diseases, and neurological disorders have fueled the demand for targeted therapies, boosting interest in aptamer-based treatments.

Robust Healthcare Infrastructure: North America's well-developed healthcare system supports advanced research in biotechnology and pharmaceuticals, facilitating the growth of the aptamers market.

Increased Interest in Aptamer R&D: Research laboratories and institutions in the U.S. and Canada are increasingly focusing on aptamer research to explore novel treatments and diagnostic tools.

An example of North America’s commitment to aptamer R&D is seen in Noxxon Pharma's announcement in April 2022. The company presented the results of its NOX-A12 GLORIA trial for treating brain cancer at the American Society of Clinical Oncology annual meeting, underscoring the region's significant advancements in aptamer-based therapies.

Asia Pacific Aptamers Market Trends

The Asia Pacific region is expected to witness the fastest growth in the aptamers market, with a CAGR of 26.18% during the forecast period. This rapid growth is driven by factors such as:

Approval of New Aptamer-Based Products: Regulatory approvals of aptamer-based products are accelerating market expansion. For instance, Achiko AG entered an agreement in April 2020 with the Pengurus Wilayah Nahdlatul Ulama DKI, a prominent Islamic association in Indonesia, to promote its COVID-19 diagnostic kit AptameX.

Increased Healthcare Demand: As healthcare needs grow, Asia Pacific countries, particularly China, Japan, and India, are adopting advanced technologies and investing in biotechnology.

The collaboration between Achiko AG and Pengurus Wilayah Nahdlatul Ulama DKI in Indonesia highlights the potential for aptamer-based products in diagnostic applications. This organization, which has around 90 million members, offers a significant market for innovative diagnostic tools, particularly as they address the ongoing COVID-19 pandemic.

Browse through Grand View Research's Category Biotechnology Industry Research Reports.

The global plasma fractionation market size was estimated at USD 35.8 billion in 2024 and is projected to grow at a CAGR of 8.5% from 2025 to 2030.

The global sickle cell anemia testing and screening market size was estimated at USD 425.7 million in 2024 and is projected to grow at a CAGR of 12.1% from 2025 to 2030.

Key Companies & Market Share Insights:

Leading companies in the aptamers market are actively pursuing strategies to enhance their product offerings and expand their market presence. These strategies include:

Product Modification: Companies are refining their existing aptamer products to improve efficacy and applicability across various therapeutic areas.

New Product Approvals: Firms are seeking regulatory approvals for novel aptamer-based products to strengthen their market share.

Mergers and Acquisitions: Strategic mergers and acquisitions are helping companies expand their product portfolios and enter new regional markets.

For instance, in January 2023, Aptamer Group announced a collaboration with BaseCure Therapeutics to develop Optimer-targeted therapies. Optimer technology is designed to enhance aptamer-targeted therapeutics, allowing for more precise drug delivery to target cells. This collaboration demonstrates the potential for aptamers in therapeutic applications and reflects the ongoing trend of partnerships within the industry aimed at driving innovation and broadening the use of aptamers in medical treatments.

Key Aptamers Companies:

SomaLogic

Aptamer Group

Aptadel Therapeutics

Base Pair Biotechnologies

Noxxon Pharma

Vivonics Inc.

Aptagen, LLC

TriLink Biotechnologies

Altermune LLC

AM Biotechnologies

Order a free sample PDF of the Aptamers Market Intelligence Study, published by Grand View Research.

[industrynewsupdates]

Aptamers Market Size, Key Companies, Trends, Growth and Forecast Report, 2030

The global aptamers market size was valued at USD 1.94 billion in 2022 and is expected to grow at a compounded annual growth rate (CAGR) of 24.54% from 2023 to 2030. 

Recent advancements in the generation, purification, and drug delivery for killing target cells have attracted the attention of many researchers towards aptamers due to the competitive advantages associated with them. Some of the advantages include small molecular size, low immunogenicity, low cost of manufacturing, and lesser side effects compared to antibodies; may fuel the R&D of novel aptamers, thereby driving market growth. Despite significant efforts, there are currently no highly effective treatments available against COVID-19 infections due to a large number of genetic mutations. However, biotechnological approaches appear to be promising in the treatment of COVID-19.

Consequently, nucleic-acid based aptamers & peptide aptamers might be effective against treating COVID-19 infection. Thus, various initiatives are being undertaken by the government to boost the R&D of novel treatment for COVID-19. For instance, in September 2020, the Department of Community & Economic Development awarded a contract of USD 320,000 to Aptagen LLC for the research and development of novel treatment for the COVID-19.

Gather more insights about the market drivers, restrains and growth of the Aptamers Market

Aptamers Market Report Highlights

• The nucleic acid aptamers segment dominated the market in 2022. The segment is set to grow at a rapid pace into areas such as therapeutics, diagnostics, research and development consumables, and biomarker discovery

• The research and development segment dominated the market in 2022 due to the growing interest of companies in aptamers; moreover, the rising awareness level coupled with favorable government initiatives are expected to stimulate the market growth of this applications segment during the study period

• The diagnostics segment is expected to be the fastest-growing segment during the forecast period due to the rising demand for aptamer-based diagnostic kits for the early diagnosis of diseases. For instance, in July 2021, SomaLogic and the CM Life Sciences announced the supply of 7,000-plex SomaScan Assay kits & SomaScan data to Beth Israel Deaconess Medical Center (BIDMC) for proteomics research

• North America dominated the market in 2022 due to the presence of key biopharmaceutical companies such as SomaLogic, IVERIC Bio, Inc., Aptagen LLC, Base Pair Biotechnologies, and their strategic initiatives for the development of new aptamers

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global live cell imaging market size was valued at USD 2.48 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 9.0% from 2024 to 2030.

• The global market for cell-free protein expression reached a value of USD 267.4 million in 2023 and is projected to grow at a CAGR of 8.6% from 2024 to 2030.

Aptamers Market Segmentation

Grand View Research has segmented the global aptamers market on the basis of type, application, and region:

Aptamers Type Outlook (Revenue, USD Million; 2018 - 2030)

• Nucleic Acid Aptamer

• Peptide Aptamer

Aptamers Application Outlook (Revenue, USD Million; 2018 - 2030)

• Diagnostics

• Therapeutics

• Research & Development

• Others

Aptamers Regional Outlook (Revenue, USD Million; 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o Germany

o UK

o France

o Italy

o Spain

o Denmark

o Sweden

o Norway

• Asia Pacific

o Japan

o China

o India

o Australia

o Thailand

o South Korea

• Latin America

o Brazil

o Mexico

o Argentina

• MEA

o South Africa

o Saudi Arabia

o UAE

o Kuwait

Order a free sample PDF of the Aptamers Market Intelligence Study, published by Grand View Research.

[mrfr-blogs]

Research Report on Global Aptamers Market: Size and Trends

Market Overview –

Aptamers market size is expected to reach USD 2.3 billion by 2022. The Aptamers market industry is expected to increase from USD 2.74 billion in 2023 to USD 11.42 billion in 2032, with a compound annual growth rate (CAGR) of 19.50% during the forecast period (2023-2032).

The Aptamers Market is expanding rapidly, driven by the increasing interest in aptamer therapeutics for various medical applications. Aptamers are single-stranded DNA or RNA molecules that bind to specific targets, offering potential advantages over traditional therapeutics. The market offers a range of aptamer-based drugs and diagnostics, promising innovative solutions for treating diseases and improving patient outcomes.

The aptamers market is witnessing significant growth due to the versatility and specificity of these molecules in various biomedical applications. Aptamers are single-stranded DNA or RNA molecules that bind to specific target molecules with high affinity, making them promising tools for diagnostics, therapeutics, and research applications. Key drivers of market growth include the increasing demand for targeted therapies, personalized medicine, and rapid diagnostic tests.

Moreover, advancements in aptamer selection techniques, such as SELEX (Systematic Evolution of Ligands by Exponential Enrichment), are expanding the repertoire of aptamer-based products and driving innovation in the market. Additionally, collaborations between academia, biotechnology companies, and pharmaceutical firms are driving research and development efforts to commercialize aptamer-based products for various indications, including cancer, infectious diseases, and autoimmune disorders. However, challenges such as limited scalability of aptamer production, regulatory hurdles, and competition from alternative targeting technologies remain considerations for market stakeholders. Overall, the aptamers market is poised for continued growth as researchers explore new applications and optimize existing aptamer-based products for clinical use.

Segmentation –

The Global Aptamers Market has been segmented based on Type, Application, And End-User.

Based on Type, the market is segmented into Nucleic Acid and Peptide Aptamers. The dominance of the Nucleic Acid category in the Aptamers market can be attributed to the widespread use of nucleic acid-based aptamers, such as DNA and RNA aptamers, due to their high affinity, specificity, and versatility for targeting diverse biomolecules in various applications.

Based on the Application, the market is segmented into Diagnostics and Therapeutics Development. The Diagnostics category primarily focuses on the accurate and timely detection, identification, and monitoring of diseases, conditions, or health parameters through various tests, techniques, and tools.

Based on the Technology, the market is segmented into Selex, X-aptamer, and MARAS techniques. The SELEX category primarily focuses on the systematic evolution of ligands by the exponential enrichment (SELEX) process, which is used to select aptamers with high affinity and specificity for specific target molecules.

Based on the End-User, the market is segmented into Biotechnology and Pharmaceutical Companies. The Biotechnology sector that dominates Aptamers primarily focuses on harnessing the unique properties of aptamers for various applications, including targeted drug delivery, diagnostics, biomarker discovery, and therapeutics development.

Regional Analysis –

The Aptamers Market showcases distinct regional trends influenced by factors such as research funding, technological advancements, and regulatory frameworks. North America leads the market, with the United States at the forefront of aptamer research and development. Advanced biotechnology infrastructure, coupled with substantial investments in R&D, contribute to market dominance in this region.

Europe follows suit, with countries like the UK, Germany, and Switzerland making significant strides in aptamer-based therapeutics and diagnostics. In the Asia Pacific region, increasing focus on precision medicine and growing investments in healthcare innovation propel market growth, particularly in countries like China, Japan, and South Korea. Latin America and the Middle East & Africa regions also show potential for market expansion, albeit with challenges related to infrastructure and regulatory hurdles. Overall, the regional analysis underscores the importance of collaborative efforts between industry stakeholders and policymakers to realize the full potential of aptamer technologies in diverse healthcare settings.

Key Players –

Aptamers companies include SomaLogic Operating Co., Inc., Aptamer Group Inc, Aptagen LLC, Aptamer Sciences Inc., Base Pair Biotechnologies Inc., Aptus Biotech SL, TriLink Biotechnologies, AstraZeneca, AM Biotechnologies, Aptadel Therapeutics, and Ophthotech Corporation.

Related Reports –

Surgical Instrument Tracking Systems

Life Sciences BPO

Vasomotor Symptoms

Medical Payment Fraud Detection

For more information visit at MarketResearchFuture

[tamanna31]

Aptamers Market Share, Supply, Sales, Manufacturers, Competitor and Consumption 2023 to 2030

Aptamers Industry Overview

The global aptamers market size was valued at USD 1.94 billion in 2022 and is expected to grow at a compounded annual growth rate (CAGR) of 24.54% from 2023 to 2030.

Recent advancements in the generation, purification, and drug delivery for killing target cells have attracted the attention of many researchers towards aptamers due to the competitive advantages associated with them. Some of the advantages include small molecular size, low immunogenicity, low cost of manufacturing, and lesser side effects compared to antibodies; may fuel the R&D of novel aptamers, thereby driving market growth. Despite significant efforts, there are currently no highly effective treatments available against COVID-19 infections due to a large number of genetic mutations. However, biotechnological approaches appear to be promising in the treatment of COVID-19.

Gather more insights about the market drivers, restrains and growth of the Aptamers Market

Consequently, nucleic-acid based aptamers & peptide aptamers might be effective against treating COVID-19 infection. Thus, various initiatives are being undertaken by the government to boost the R&D of novel treatment for COVID-19. For instance, in September 2020, the Department of Community & Economic Development awarded a contract of USD 320,000 to Aptagen LLC for the research and development of novel treatment for the COVID-19.

The aptamers based diagnostic kits and assays developed by using SELEX technology have the ability to develop high-affinity neutralizers and bioprobes for monitoring SARS-COV-2 & COVID-19 biomarkers. Therefore, the introduction of diagnostic kits in the market for disease diagnosis is projected to drive market growth. For instance, in December 2021, Achiko AG received approval from the Ministry of Health of the Republic of Indonesia for Aptamex, a COVID-19 diagnostic kit. Aptamex is a second-generation diagnostic kit developed by using DNA aptamer-based technology that is a cost-effective, chemically synthesized, and an emerging diagnostic kit for healthcare.

Aptamers based diagnostic products are the preferred choice among diagnostic and pathology labs for the diagnosis of disease at the cellular level due to their small size, high specificity, selectivity, and efficacy. Thus, increasing prevalence of diseases such as cancer, CVD, and AMD may increase the footfall of patients in labs for the diagnosis of these diseases, consequently, increasing demand for aptamer based diagnostic products. According to Cancer Research UK estimates, around 27.5 million people are expected to be diagnosed with cancer by 2040.

In March 2022, SomaLogic announced the initiation of assaying samples using SomaScan Assay for the European Prospective Investigation into Cancer and Nutrition (EPIC) study by analyzing 210 million protein measurements from 30,000 samples. This will help researchers in predicting cancer by better understanding its nature, which in turn may contribute in market growth by addressing the increased demand.

As of now, Macugen developed by Eyetech Pharmaceuticals, Inc., (currently commercialized by Bausch Health Companies Inc.) is only the U.S. FDA approved (2004) therapeutic aptamer available in the market. It is used for the treatment of age-related muscular degeneration disorder (AMD). Technological advancements in research encourage scientists’ attention towards the development of novel aptamer based therapeutic drugs for the treatment of various diseases. Currently, there are a number of products under different clinical trials including Zimura developed by IVERIC Bio, Inc., for the treatment of patients with drug AMD. Thus, expected approval of this drug may boost the growth of the market over the period.

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global structural biology & molecular modeling techniques market size was valued at USD 7.13 billion in 2023 and is projected to grow at a CAGR of 15.4% from 2024 to 2030.

• The global targeted DNA RNA sequencing market size was valued at USD 10.12 billion in 2023 and is projected to grow at a CAGR of 19.4% from 2024 to 2030.

Global Aptamers Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the market trends in each of the sub-markets from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the aptamers market on the basis of type, application, and region.

Type Outlook (Revenue, USD Million; 2018 - 2030)

Nucleic Acid Aptamer

Peptide Aptamer

Application Outlook (Revenue, USD Million; 2018 - 2030)

Diagnostics

Therapeutics

Research & Development

Others

Regional Outlook (Revenue, USD Million; 2018 - 2030)

North America

US

Canada

Europe

Germany

UK

France

Italy

Spain

Denmark

Sweden

Norway

Asia Pacific

Japan

China

India

Australia

Thailand

South Korea

Latin America

Brazil

Mexico

Argentina

MEA

South Africa

Saudi Arabia

UAE

Kuwait

Key Companies & Market Share Insights

Major players are adopting strategies such as modification in the existing product, approval of new products, and mergers & acquisitions for product enhancements and regional expansion to attain a greater market share. For instance, in January 2023, Aptamer Group collaborated with BaseCure Therapeutics for the development of Optimer-targeted therapies. Such initiatives can open new avenues of growth for applications of aptamers in therapeutics. Some of the prominent players in the global aptamers market include:

SomaLogic

Aptamer Group

Aptadel Therapeutics

Base Pair Biotechnologies

Noxxon Pharma

Vivonics Inc.

Aptagen, LLC

TriLink Biotechnologies

Altermune LLC

AM Biotechnologies

Order a free sample PDF of the Aptamers Market Intelligence Study, published by Grand View Research.